---
title: "Validating AI-Enabled GxP Systems: A Framework That Is Still Being Built"
description: "How to validate AI and machine learning systems in regulated pharmaceutical environments: what is genuinely different about AI validation, where the regulatory framework has gaps, and a practical approach you can defend in an inspection today."
pubDate: 2026-05-25
tags: ["AI", "validation", "CSV", "GxP", "21-CFR-Part-11", "machine-learning"]
pillar: "ai-automation"
tier: "Advanced"
---

Validating AI systems in GxP environments is a live problem with no settled answer. The regulatory framework that governs traditional computerized systems, 21 CFR Part 11, GAMP 5, the FDA computer software assurance guidance, was not designed for systems whose behavior changes over time, whose internal logic is not fully interpretable, and whose performance is probabilistic rather than deterministic.

Companies are deploying AI-enabled GxP systems now, with or without a complete regulatory framework. This article is a practical guide to validating them using the best available tools, while being honest about where the framework has genuine gaps and where you have to reason from first principles.

If you have not yet built a foundation in computerized system validation, read the [GAMP 5 CSV framework](/articles/gamp5-csv-framework) and the [computer software assurance approach](/articles/computer-software-assurance-fda) first. The AI-specific work sits on top of that base; it does not replace it.

---

## What Makes AI Validation Different

Traditional computerized system validation rests on one core assumption: the system's behavior is deterministic and stable. Given the same inputs, the system produces the same outputs. The validation test proves those outputs are correct, and as long as the system does not change, the validation stays valid.

AI and machine learning systems break that assumption in several ways.

**Model behavior is probabilistic.** A machine learning model does not guarantee a specific output for a specific input. It produces a prediction with an associated confidence or probability. Two runs of the same model on the same data can produce slightly different results when the model has any stochastic element, for example dropout left active at inference, or non-deterministic floating-point operations on a GPU. A validation test that asserts an exact output value will be brittle in ways that traditional script-based testing is not.

**Models can change without a traditional software update.** A model that continues to learn from new data changes its behavior over time without any discrete version change in the code base. The validation that was accurate at deployment may no longer represent the system's behavior after several months of operation. Even a model that is frozen at deployment can effectively change behavior because the data flowing into it has shifted, a phenomenon usually called data drift or concept drift.

**The logic is not fully interpretable.** Traditional software logic can be read, inspected, and reasoned about line by line. Deep learning models produce outputs through layered mathematical transformations across thousands or millions of parameters. You cannot point to the line of code that made the decision, which makes it difficult to write test cases that definitively cover all relevant behaviors. For a regulated decision, the inability to explain why a model reached a conclusion is not a cosmetic problem; it directly affects whether a human reviewer can exercise meaningful judgment over the output.

**Performance metrics, not specifications, govern behavior.** A traditional validation states that "the system shall accept a valid result entry and display it in the audit trail," a binary pass or fail. An AI validation might state "the model shall classify incoming deviation reports with an F1 score of at least 0.90 on a representative held-out test set." That is a statistical claim about aggregate behavior across a population, not a guarantee about any single record. The acceptance criterion is a number on a curve, not a yes-or-no behavioral assertion.

The practical consequence: you cannot simply lift a traditional validation protocol and run an AI system through it. The structure of the evidence is different. You are proving a performance distribution, managing its stability over time, and wrapping it in human controls, rather than proving a fixed input-output table once and freezing it.

---

## Current Regulatory Guidance and Its Limits

As of mid-2026, there is no single FDA guidance dedicated to validating AI and machine learning systems used in pharmaceutical manufacturing or quality operations. The documents that apply were written for adjacent problems, and you borrow principles from them rather than following a recipe.

| Reference | What it covers | What it does not cover |
|---|---|---|
| FDA AI/ML-Based Software as a Medical Device Action Plan (January 2021) | Transparency, predetermined change control plans, real-world performance monitoring for AI in devices | Manufacturing and quality-system AI; the action plan is a SaMD device document |
| FDA Computer Software Assurance for Production and Quality System Software guidance (final, 2025) | Risk-based, intended-use-driven assurance; critical thinking over documentation volume | AI-specific risks such as drift, explainability, and continuously learning models |
| GAMP 5 Second Edition (ISPE, 2022) | Risk-based CSV; appendices on distributed ledger, AI/ML, and other novel technologies | A complete, prescriptive AI validation protocol; it gives principles, not steps |
| 21 CFR Part 11 (electronic records and signatures) and EU GMP Annex 11 | Audit trails, access control, electronic record and signature integrity | Anything specific to probabilistic or learning systems |

A few notes on each.

The **FDA AI/ML SaMD Action Plan** is a device document, not a manufacturing document, so it does not govern a quality-operations model directly. It is still worth reading because it introduced the predetermined change control plan, a mechanism for describing intended model changes in advance and the testing that accompanies them. That concept transfers cleanly to manufacturing and quality AI even though the legal pathway does not. FDA later issued draft guidance in 2025 on marketing submissions for AI-enabled device software functions that expands the predetermined change control plan concept; again useful for ideas, not binding on a quality-system model.

The **computer software assurance guidance** does not mention AI in any depth, but its central principle is the right starting point: scale your assurance activities to the risk the software poses to product quality and patient safety, defined by intended use, and prefer critical thinking and targeted testing over documentation for its own sake. Applied to AI, that means concentrating your evidence on the performance characteristics that actually matter for the intended use, not generating volume.

**GAMP 5 Second Edition** added material on novel and innovative technologies, including machine learning, and ISPE has published supplementary good-practice material in this area. The enduring GAMP principle holds: calibrate validation effort to risk, with risk defined by intended use and the nature of the software. The second edition also draws more on supplier capability and the critical-thinking model that aligns with the assurance guidance.

**The gap that matters:** none of these documents tells you how to demonstrate that a model which keeps learning remains in a validated state, how much explainability a regulated decision requires, or what statistical evidence is sufficient for a given risk class. The industry is operating ahead of the formal guidance, and inspectors know it. That is not a reason to wait; it is a reason to document your reasoning carefully so the rationale survives an inspection.

---

## A Practical Validation Framework for GxP AI

Given the gaps, here is a framework grounded in existing regulatory principles that also addresses the AI-specific problems. It follows the familiar validation lifecycle, with AI-shaped content inside each stage. For the underlying lifecycle and document set, see the [validation deliverables guide](/articles/validation-deliverables-guide).

### 1. Define the Intended Use Precisely

The single most important design decision is stating exactly what the system does and what role the AI output plays in the regulated workflow. Get this wrong and every downstream activity is mis-sized.

There are at least three distinct AI use patterns in GxP, each with different validation implications.

**Advisory or screening.** The AI flags potential issues for human review, and a person makes the final determination. The AI is a screening tool, not a decision-maker. This is the lowest-risk pattern and the easiest to validate. The validation shows that the flags are useful at the intended sensitivity, meaning the false-negative and false-positive rates are acceptable for the screening purpose, and that the human review process is defined and recorded. Example: a model that surfaces audit trail entries most likely to be data-integrity relevant so a reviewer can prioritize, while the reviewer still examines the full set on a defined sampling basis.

**Automated classification.** The AI classifies records such as deviations, complaints, or documents without per-record human review, and that classification drives downstream actions. The risk is higher because the model's output is acted upon directly. The validation must demonstrate classification performance at the level the use case requires, and the monitoring program must reliably detect performance degradation before it causes harm. Example: auto-routing incoming events to the correct quality workflow based on text content.

**Process control.** The AI influences a manufacturing parameter such as feed rate, temperature, or agitation based on model predictions. This is the highest-risk pattern. The validation must include failure-mode analysis for model failures, and the system must have engineered safety interlocks that prevent the model from driving the process outside validated operating bounds, independent of the model itself. The interlock is a deterministic control you can validate the old way; it is what keeps a probabilistic component inside a defensible envelope. This sits on top of the conventional [automation and control system validation](/articles/automation-validation-plc-scada-dcs) for the underlying equipment.

A useful discipline: write a single sentence that names the model output, the action it triggers, and the person or system accountable for the consequence. If you cannot write that sentence cleanly, the intended use is not yet defined.

### 2. Apply GAMP Software Categories With AI-Specific Nuance

An AI system in a GxP context is usually GAMP Category 5 (custom software) or Category 4 (configured commercial product).

- **Category 4.** A commercial platform with built-in machine learning capability, configured for a specific GxP use. The vendor develops and maintains the ML infrastructure; your site owns the training data, the configuration, the model selection, and the deployment. Vendor assessment carries weight here, but note that a vendor's general claim of "validated AI" rarely covers your specific model trained on your data for your intended use. The configured, trained instance is yours to validate.
- **Category 5.** A model built and trained specifically for the use case. All development, training, and deployment are site activities, and the validation is correspondingly the most demanding: documented model development, training-data management, a defined testing methodology, and change control for model updates.

A subtlety that trips teams up: even a Category 4 platform produces a Category 5-like artifact once you train a custom model inside it. The platform is configured; the model is, in effect, bespoke. Size your evidence to the trained model's risk, not to the platform's marketing category.

### 3. Define Performance Specifications Before You Train

Where traditional software is tested against functional specifications, AI models are tested against performance specifications. Common metrics:

- **Sensitivity (recall):** the proportion of true positives the model correctly identifies. Critical when a missed positive is the dangerous failure, for example a missed critical deviation.
- **Specificity:** the proportion of true negatives the model correctly dismisses. Critical when false alarms carry cost or erode trust in the system.
- **Precision (positive predictive value):** of the items the model flagged, how many were truly positive.
- **F1 score or another composite** that balances precision and recall when both matter.
- **Confidence calibration:** whether the model's stated confidence matches observed accuracy. A model that says it is 90 percent confident should be right about 90 percent of the time at that confidence level. Poor calibration quietly undermines any workflow that routes by confidence threshold.

The acceptance criteria belong in the user requirements specification, defined before the model is trained and tested. If you measure performance first and then write the specification to match, you have fitted your criteria to the result, which is not testing, it is rationalization. Decide what performance the intended use genuinely requires, justify the threshold against the consequence of error, then build and test against it.

One more discipline that inspectors increasingly probe: hold out a true test set that the model never saw during training or tuning, and keep it under version control. Performance reported on data the model trained on is meaningless as validation evidence. The held-out set, ideally drawn from a time period after the training data to mimic real deployment, is your honest measure.

### 4. Training Data Integrity

For supervised models, the training data is a regulated resource. The integrity of the model is bounded by the integrity of the data it learned from, so the same [data integrity foundations](/articles/data-integrity-foundations) that govern any GxP record apply here, with additions specific to model building. Address:

- **Source and lineage.** Where did the data come from, was it GxP data, and was it handled under controls when it was created? Garbage-but-attributable is still garbage for training purposes.
- **Representativeness.** Does the training data reflect the population the model will face in production, across products, sites, instruments, and edge cases? A model trained on data from one product line will quietly underperform on another.
- **Labeling quality.** Were labels generated by qualified subject-matter experts, and for subjective judgments, what was the inter-rater agreement? A model can only be as consistent as the labels it learned from. Document the labeling procedure and the qualifications of the labelers as you would any other GxP determination.
- **Version control.** Is the exact training dataset versioned so the model can be reproduced? Reproducibility is the AI analogue of a retained record. If you cannot rebuild the model, you cannot investigate it.
- **Production data used for retraining.** Data pulled from the production environment to retrain a deployed model is itself GxP data and carries the full [ALCOA+ data integrity expectations](/articles/alcoa-plus-deep-dive). Retraining is a data-integrity event, not just an engineering task.

### 5. Model Change Control

Model updates, whether retraining, architecture changes, or hyperparameter changes, are system changes in the validation sense and require [change control](/articles/change-control-validated-systems). The difficulty is that "model update" spans a wide range, from a full architecture replacement that clearly demands revalidation, to a minor retrain on a small batch of new data that may need only a confirmatory check.

A predetermined change control plan, the concept FDA introduced for SaMD in the 2021 action plan, applies well to manufacturing and quality AI. A good plan, written and approved before deployment, defines:

- which types of model change are anticipated and in scope;
- the performance boundaries that trigger or constrain a change;
- the testing required for each class of change;
- the threshold at which a change requires full revalidation rather than a confirmatory update.

With this plan in place, routine model maintenance proceeds in a controlled way instead of every retrain being treated as an unplanned deviation. Without it, you face a choice between revalidating constantly or letting changes slip through ungoverned; neither is defensible. A worked example: the plan might permit quarterly retraining on accumulated production data, provided the retrained model meets or exceeds the original performance specification on the held-out test set and the input distribution has not shifted beyond defined limits, with a documented confirmatory test record for each retrain and a hard requirement for full revalidation if the architecture or feature set changes.

### 6. Performance Monitoring After Deployment

The validated state of an AI system includes ongoing performance monitoring: periodic evaluation against the performance specification in the requirements, using representative samples from production. This is the AI equivalent of the periodic review every validated system needs, described in the [validation master plan and periodic review](/articles/validation-master-plan-and-periodic-review) article. The difference is what you are checking. Periodic review of a traditional system confirms the software has not changed (configuration verification). Periodic review of an AI system confirms performance has not degraded, which can happen with no intentional change at all, because the world the model sees has moved.

Triggers for a model performance review:

- scheduled cadence, for example quarterly;
- a shift in the input data distribution, such as a new product, process, or instrument;
- stakeholder feedback indicating unexpected behavior;
- an override rate above a predefined threshold, meaning human reviewers are correcting the model more often than expected.

Build the monitoring in from day one. A model with no monitoring is not in a validated state regardless of how it performed at release, because you have no evidence it still works. The monitoring evidence is itself a GxP record and should be retained and reviewable.

---

## Explainability and the Regulated Decision

Explainability deserves its own treatment because it determines whether human review can be meaningful at all. A reviewer cannot exercise judgment over a conclusion they cannot interrogate. The level of explanation you need scales with risk and with the use pattern.

For an advisory model, a confidence score and the top features driving the flag may be enough for a reviewer to decide where to look. For an automated classification that drives action, you generally want a per-decision rationale: the input features that most influenced the output, similar past cases, or a natural-language justification the reviewer can sanity-check. For process control, the deterministic interlock matters more than the model's self-explanation, because you are relying on engineered bounds rather than the model's reasoning.

Be cautious with post-hoc explanation techniques. Methods that attribute a prediction to input features are useful for review and for investigation, but they are approximations of the model's behavior, not a literal account of it. Treat them as an aid to human judgment, document their limitations, and do not present an approximate attribution as if it were a guaranteed causal explanation. An honest statement of what the explanation does and does not establish is more defensible than overclaiming.

---

## Human Review: The Non-Negotiable Control

For any AI operating in a GxP context, human review is not optional. It is the control that keeps the system consistent with the GxP principle that quality decisions require documented human judgment. The human review step must be:

- **Defined.** What does the reviewer actually do, what information do they see, and what decision are they making? Vague review steps fail in inspection.
- **Documented.** The reviewer's conclusion goes into a GxP record, together with the AI output that was reviewed and, where relevant, the model version that produced it.
- **Meaningful.** Reviewers are trained on the system's performance characteristics, including its known weaknesses, and apply judgment rather than rubber-stamping outputs. Training records should reflect this.

The hardest part to sustain is meaningfulness. A model that is right almost all the time breeds automation bias: reviewers start approving without truly reviewing, precisely because the model is usually correct. That erodes the only control standing between a model error and a quality event. Design the workflow to keep reviewers genuinely engaged. Present the model's reasoning, not just its conclusion. Require a short justification when a reviewer agrees with a high-confidence output. Monitor the rate at which outputs are accepted without modification, and treat an unusually high acceptance rate as a signal to investigate, not as success. The same vigilance that drives effective [audit trail review](/articles/audit-trail-design-and-review) applies here: a control that is never exercised is not a control.

---

## How This Plays Out in an Inspection

Inspectors approaching an AI-enabled GxP system tend to ask a predictable set of questions, and your documentation should answer them before they are asked. Expect: What is the intended use and what decision does the model drive? How was the model validated, against what acceptance criteria, and were those criteria set before testing? Where did the training data come from and how is its integrity assured? How do you control model changes? How do you know the model still performs, and what do you do when it drifts? What is the human review step and how do you keep it meaningful?

The recurring theme across the broader inspection patterns, covered in [FDA inspection readiness](/articles/fda-inspection-readiness), is that investigators reward a coherent, honestly documented rationale and penalize gaps that look unmanaged. An AI system whose file says, in effect, "here is what we validated, here is the principle we applied where guidance was silent, here is how we monitor it, and here is the human control," reads as a system under control. One that claims blanket compliance under a framework that visibly does not fit invites deeper scrutiny.

---

## The Honest Assessment

AI validation in GxP is being worked out by industry and regulators in parallel, without a complete answer yet. Companies deploying AI in regulated environments today do so under frameworks that were not designed for AI, with the understanding that more specific guidance will arrive in time.

Waiting for perfect guidance carries its own risk, because the guidance may be years away and the operational pressure to deploy is already here. Deploying with no framework carries the opposite risk: when inspectors eventually look closely, your readiness will be unclear and difficult to reconstruct after the fact.

The path I would recommend is steady and unglamorous. Use the best available frameworks, GAMP 5, the computer software assurance approach, Part 11 and Annex 11. Be explicit about where they apply cleanly and where you are reasoning by analogy. Document the rationale for every design decision that existing guidance does not cover, so the thinking is visible later. Set performance criteria before you test, keep training data under integrity controls, govern model changes with a predetermined plan, and build monitoring in from the first day of operation.

A deployment with honest documentation of both what was validated and what remains uncertain is more defensible than one that claims full compliance under a framework that does not quite fit. Regulators generally respond better to well-managed, openly stated uncertainty than to confident compliance claims that come apart under questioning.
